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Objective. Limited information exists on features of pediatric Selective IgM immunodeﬁciency (SIgMID). Previously published
pediatric cases and 2 new cases are reviewed. Methods. English literature from PubMed and references from relevant articles
were reviewed. Previously reported cases and 2 new cases from an allergy/immunology practice were analyzed. Results.F o r t y -
nine reported cases of SIgMID presented with respiratory infections (77.6%), gastrointestinal disease (16.3%), skin disease
(12.2%), and meningitis (8.2%). Mean serum IgM level was 16.5 ± 13.8mg/dL. Two patients were identiﬁed with SIgMID
among 6300 active pediatric patients (0.03%) presenting with asthma, vasomotor rhinitis, and recurrent respiratory infections.
In the 51 cases reported, none developed lymphoproliferative disease nor evolved into panhypogammaglobulinemia; four
fatalities were reported. Conclusions. The prevalence of SIgMID in our pediatric population was 0.03%. In general, respiratory
infections are the common comorbid conditions. Death and autoimmune disease are uncommon complications of pediatric
SIgMID.
Copyright © 2008 Marc F. Goldstein et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Selective IgM immunodeﬁciency (SIgMID) is a dysgam-
maglobulinemia characterized by an isolated low level of
serum IgM, usually <20mg/dL in infants and children or
<2 standard deviations or 10% below age adjusted means
[1–3]. Usually, serum IgM levels are <10–20mg/dL [3].
The level of other immunoglobulin isotypes is typically
normal, although IgE may be increased. It is said to be
a rare primary immunodeﬁciency, with the prevalence of
completely deﬁcient IgM patients reported as approximately
0.03% in a community-based study. [1] However, the
prevalence of those with deﬁcient but detectable levels of
IgM is closer to 0.1–3.0% in hospitalized patients [1, 4, 5],
1.6% in an unselected community health screening [1, 6],
0.07% in an allergy and immunology clinic [7], and 0.26%
in an adult allergy and immunology clinic [8]. There is
a slightly higher penetration of SIgMID in males (1.97%)
versus females (1.42%) [1]. The prevalence in the pediatric
population (<18 years of age) has not been reported.
A variety of bacterial and viral infections have been
linked with SIgMID in the pediatric and adult populations
(Table 1)[ 8]. In children, infectious agents have included
Pneumocystis carinii [9], Giardia [10], Staphylococcus [10,
11], Salmonella [12], Listeria monocytogenes [13], meningo-
coccus [6, 14, 15], Pseudomonas [10, 16], molluscum con-
tagiosum [17], cytomegalovirus [18], and varicella [17].
These organisms account for recurrent infectious dermatitis,
diarrhea, meningitis, upper and lower respiratory infections,
sepsis, and in some cases, death. Secondary IgMID presump-
tivelyfromanothercausehasbeenassociatedwithanarrayof
noninfectious diseases in children and adults, in particular,
autoimmune diseases and malignancies [8]. In children,
celiac disease and autoimmune hemolytic anemia (Table 1)
have been reported but other autoimmune diseases and
malignancies have not. We present a review of 49 previously
reported pediatric patients with SIgMID and 2 new cases
fromourpractice.Therelativefrequenciesofvariousclinical,
immunological and demographic features, associations, and
complications are established in this series. These ﬁndings2 Clinical and Developmental Immunology
are also compared and contrasted to adult cases previously
reported [8].
2. MATERIALS AND METHODS
We undertook a retrospective (2002–2005) medical record
review of 20000 charted patients seen in our practice over
a 3-year period. Of these, 6300 patients were children (<18
years of age). Charts were selected with a diagnosis of
SIgMID,selectiveIgAimmunodeﬁciency(SIgAID),common
variable immunodeﬁciency (CVID), Bruton agammaglobu-
linemia, and transient hypogammaglobulinemia of infancy
andreviewedforimmunoglobulin levels(IgG,IgM,IgA,IgE,
and IgG subclasses), isohemagglutinin levels, autoantibody
serologies, presenting clinical symptoms, concurrent condi-
tions, and clinical course. Patients diagnosed with SIgMID
were screened serologically for celiac disease, autoimmune
thyroid disease, and autoimmune collagen vascular disease.
A literature search was conducted of reported cases of SIg-
MID in the English literature through PubMed from 1966,
and from the bibliographies of related articles. Identiﬁed in
the literature were 361 previously reported SIgMID patients,
comprisedof155adult,49pediatric,and157ageunspeciﬁed
patients. The analyses of the 155 adult, 157 age-unspeciﬁed
cases,and36newadultcasesofSIgMIDhavebeenpreviously
reported [8]. Comparative analysis was made of clinical,
laboratory, and demographic data of pediatric cases to
reported adult cases of SIgMID.
3. STATISTICAL ANALYSIS
The group mean and 1 SD were calculated for group serum
IgM, IgA, IgG, IgE levels and age of presentation. Descriptive
statistics were used to denote frequencies of occurrence of
comorbid conditions. Statistical analyses were done with
Microsoft Excel (Microsoft Corporation, Redmond, WA).
4. RESULTS
4.1. Previouslyreportedpediatriccases
Forty-nine previously described pediatric cases of SIgMID
were identiﬁed ranging in age from 1 month to 17 years
(Table 1). The mean age at the time of diagnosis was 6.0±4.7
years. Of these cases, where reported, presenting respiratory
infections occurred in 78.4% of cases (Table 2). Frequencies
of speciﬁc presenting respiratory infections were otitis media
(39.2%), pneumonia/lower respiratory infections (19.6%),
bronchitis (9.8%), and upper respiratory infections (9.8%).
Frequency of nonrespiratory presenting illnesses included
gastrointestinal illness (13.7%), skin disorders (9.8%) with
atopic dermatitis the most common (6.1%), failure to thrive
(7.8%), asthma (7.8%), meningitis (7.8%), and vasomotor
rhinitis (3.9%). Five patients had celiac disease and serum
IgM levels normalized in all cases on gluten free diets.
There were no patients with malignancies reported. There
were 2 asymptomatic cases reported. The mean serum
IgM level was 16.5 ± 13.8mg/dL. Serum IgA and IgG
levels were normal in all cases. Mean serum IgE level was
elevated at 1814 ± 3509IU/mL. Four patients developed
respiratory allergy while 3 patients developed asthma. Two
patients lacked protective IgG responses to polysaccha-
ride and protein antigen/vaccine challenge and clinically
responded to intravenous immunoglobulin (IVIg) treat-
ment. Where tested, most patients had low-to-normal titers
of IgM isohemagglutinins. Infections from pneumococ-
cus, Staphylococcus, Pseudomonas, Salmonella, Pneumocystis
carinii, Giardia,c y t o m e g a l o v i r u s ,Listeria monocytogenes,
meningococcus, molluscum contagiosum, and varicella were
reported.
4.2. Pediatriccohort
Sex and Race: there were 2 Caucasian males and 0 females
identiﬁed in our pediatric population of 6300 patients.
Age at time of diagnosis: age of diagnosis of SIgMID was
10 (patient 1) and 12 years of age (patient 2). Onset of
SIgMID could not be determined or estimated accurately,
although patient 1 had normal IgM, IgG, IgA levels 6 years
prior to diagnosis. Observation Period: patient 1 had been
followed for 8 years and patient 2 for 5 years post diagnosis.
Immunoglobulin Levels: two patients in our pediatric patient
population of 6300 (incidence 0.03%) were identiﬁed with
reduced serum IgM levels less than 2 SD of age-adjusted
means. Asymptomatic patients may have been missed since
only symptomatic patients with recurrent infections or
unusual infection were screened for immunodeﬁciency. Nei-
therpatienthadundetectableIgMlevels.TheserumIgMlev-
els were 21mg/dL (patient 1) and 30mg/dL (patient 2) with
normal serum IgA, serum IgG levels, and IgG subclasses.
The serum IgE level was 15IU/ml in patient 1 [normal
levels (<200IU/ml)]. Immunoglobulin levels were repeated
6 months and 2, 4, and 7 (patient 1) years after diagnosis and
remained essentially the same with persistence of serum IgM
<30mg/dL in both patients through time. Within the same
database of patients there were no pediatric patients with
CVID,Brutonagammaglobulinemia,transienthypogamma-
globulinemia of infancy, or SIgAID. Serologic Evaluation:
becauseofpreviousreportsofautoimmunedisease,thyroidi-
tis, and celiac disease in patients with SIgMID, the 2 patients
were screened for anemia, ANA, anti-endomysial antibody,
anti-gliadin antibody, anti-transglutaminase antibody, and
thyroid autoantibodies. No autoantibodies were identiﬁed
in either patient. Neither patient was anemic. Functional
Antibodies: both patients were tested for ABO blood group
and isohemagglutinin level. Detectable low titer isohemag-
glutinins were noted (patient 1 anti-A 1:4; patient 2 anti-B
1:8). IgG antibody responses to tetanus, H. inﬂuenzae,a n d
pneumococcus vaccination were normal.
Clinicalmanifestations
Infections: our 2 patients presented with a history of res-
piratory infections: patient 1 with recurrent otitis media
and patient 2 with pneumonia. Neither patient had a severe
life-threatening infection. Neither patient had an unusual
bacterial, viral, fungal, or parasitic infection, meningitis,
bacteremia,orabscesspriortoorduringthefollowupperiod.Marc F. Goldstein et al. 3
Table 1: Characteristics of previously reported pediatric cases of SIgMID. WNL: within normal limits, GN: glomerulonephritis, CMV:
cytomegalovirus, AD: atopic dermatitis, N/A: not available, OM: otitis media, URI: upper respiratory infection.
Reference Age of diagnosis
(year)/sex
Presenting
history
Serum IgM
mg/dL
Serum IgG
mg/dL
Serum IgA
mg/dL IgE IU/mL Comment
[19] 9m a l e
Pyoderma, AD,
diarrhea, cuta-
neous candidi-
asis, rudimen-
tary auricles
1/4o fn o r m a l
controls WNL WNL N/A
⊕Isohemaggluti-
nin; Lack of IgM
response to S. ty-
phi; “O” antigen
[9] 4.5m of e m a l e
Autoimmune
anemia, GN,
failure to thrive
13 2500 390 N/A
Died of PCP; dif-
fuselymphoidhy-
poplasia, thymus
dysplasia
[6] 8m a l e
Meningococcal
sepsis, Waterh-
ouse-Friderich-
sen syndrome
4 560 70 Died from infec-
tion
[6] 5m a l e Meningococcal
meningitis 12 1120 190 Died from infec-
tion
[20] 3 Celiac disease 33 N/A N/A N/A
IgM level norma-
lized after gluten
free diet
[20] 8 Celiac disease 30 N/A N/A N/A
IgM level norma-
lized after gluten
free diet
[20] 10 Celiac disease 35 N/A N/A N/A
IgM level norma-
lized after gluten
free diet
[20] 13 Celiac disease 40 N/A N/A N/A
IgM level norma-
lized after gluten
free diet
[20] 2 Celiac disease 20 N/A N/A N/A
IgM level norma-
lized after gluten
free diet
[21] 5 male Asymptomatic 35 820 224 N/A Familial cases
[2] 3.75 male N/A 7 495 172 N/A
Partialdeletionof
long arm ofchro-
mosome 18
[12] 6m a l e
Recurrent pn-
eumonia, OM,
AD, sinusitis
6 1250 950
ReceivedIMgam-
maglobulin treat-
ment, salmonella
enteritis, pneum-
ococcal sepsis
[16] 8.5momale
Pseudomonas
pneumonia,re-
current OM
0W N L M i l d l y r e d u c e d Died from infec-
tion
[18] 13 male CMV hepatitis 26–29 N/A N/A N/A
[14] 4 Meningitis 34 WNL WNL N/A
Low IgM hemag-
glutinin to meni-
ngococcus
[14] 1 Asymptomatic 36 WNL WNL N/A
Low IgM hemag-
glutinin to meni-
ngococcus4 Clinical and Developmental Immunology
Table 1: Continued.
Reference Age of diagnosis
(year)/sex
Presenting
history
Serum IgM
mg/dL
Serum IgG
mg/dL
Serum IgA
mg/dL IgE IU/mL Comment
[22] 2.5f e m a l e
Recurrent OM,
laryngitis,men-
ingitis
8 530 48 N/A
Absent isohem-
agglutinin, chr-
omosome#1de-
fect
[1] 3 patients,
female <17 N/A <23 WNL WNL N/A
[1] 7 patients, male
<16 N/A <23 WNL WNL N/A
[23] 12 female
Recurrent bron-
chitis, OM, pne-
umonia, bronc-
hiectasis
34 686 87 N/A
No response to
salmonella “H”
antigen
[24] Young male N/A 8 1500 72 555
[10] 3f e m a l e erythrodermic
psoriasis <4 680 125 340
OM, diarrhea,
failure to thr-
ive, recurrent
respiratory in-
fection, eosin-
ophilia
[10] 9m a l e A D <4 900 153 8000
Failure to thr-
ive, recurrent
respiratory tra-
ctinfectionand
pneumonia, sk-
ininfections,gi-
ardiasis, eosino-
philia
[17] 16 female
Disseminated
molluscumco-
ntagiosum
<4 2305 688 8900
AD, aphthous
stomatitis, va-
ricella, recurr-
entrespiratory
infections,eos-
inophilia, bro-
nchiectasis
[25] 2.5f e m a l e Failure to thrive,
recurrent URI 37 869 45 N/A
[25] 5.5f e m a l e
Failuretothrive,
recurrent OM,
eyelidandGIin-
fections
38 1064 42 N/A
[25] 8m a l e
Failuretothrive,
recurrent OM,
eyelidandGIin-
fections
42 488 100 N/A
[26] 1mo Pneumonia <6 <350 N/A N/A
NonspeciﬁcIgG
subclass deﬁcie-
ncy
[26] 11mo Bronchitis, OM <4 <350 N/A N/A
[26] 3 Bronchitis, OM 5 780 N/A N/A
[26] 2O M 1 1 ∼2200 N/A N/A
[13] 1mo Meningitis,
pneumonia, OM 6 717 27 <10 Allergic rhinitis
[13] 3 Bronchitis, OM 5 768 108 <10 Allergic rhinitis
[13] 2 OM 11 608 33 12 Allergic rhinitisMarc F. Goldstein et al. 5
Table 1: Continued.
Reference Age of diagnosis
(year)/sex
Presenting
history
Serum IgM
mg/dL
Serum IgG
mg/dL
Serum IgA
mg/dL IgE IU/mL Comment
[13] 11mo OM, pneum-
onia 5 462 25 <10
[13] 11mo Bronchitis,OM 5 345 88 <10 Wheezing
[13] 8 OM, pneum-
onia 11 925 134 297 Allergic rhinitis,
wheezing
[27] 10 male
Recurrent sin-
usitis,OM,pn-
eumonia, chro-
nic staphyloco-
cci blepharitis
23 900 86 N/A
[28] 15 female Chronic OM <6 1170 356 N/A 22q11.2 chrom-
osome deletion
[3] 11 male Asthma <5N L N L N / A Father with
SIgMID
[29] 17 male
Russell-Silver
Syndromewi-
th recurrent
URI
1N L N L N / A
No response to
pneumococcal
vaccine
[30] 1.5 male Recurrent OM 28 N/A N/A N/A
[31] 7
Recurrent OM,
pneumococcal
pneumonia wi-
th emphysema
Deﬁcient NL NL Elevated
Lack of protect-
ive antibody re-
sponsetopolys-
accharide and
protein antigen,
responded to
IVIg
[31] 18 month
Asthma, recur-
rent OM, pseu-
domonal pneu-
monia, sepsis
Deﬁcient NL NL Elevated
Mean 6 ±4.71 6 .5 ±13.8 939 ±580 183 ±226 1814 ±3509
Gastrointestinal Abnormalities: chronic gastrointestinal ill-
nesseswerenotnoted.Autoimmune Disease:noaut oimmune
disorders were noted at time of presentation or during
the followup period. Other Respiratory Conditions including
Allergy: upper respiratory allergies were ruled out by skin
testing. Other noninfectious respiratory conditions seen
included asthma and vasomotor rhinitis in both patients.
Neither patient had nasal polyps. Miscellaneous Abnormali-
ties: neither idiopathic angioedema nor idiopathic anaphy-
laxis was seen. During the followup period of observation,
neither patients transformed into CVID. Mortality: neither
patient died of serious infections, malignancies or complica-
tionsofautoimmunedisease.Family History of Patients:there
werenofamilyhistories ofinfantile deaths,increased suscep-
tibility to infections, or primary immunodeﬁciencies among
immediate relatives. Screenings for immunodeﬁciencies in
parents and siblings were recommended but compliance was
inconsistent. Where tested, no parent or sibling was iden-
tiﬁed with an immunoglobulin deﬁciency. Therapy: neither
patient was put on IVIg therapy. In general, infections were
successfully treated with conventional courses of antibiotics.
5. DISCUSSION
Immunoglobulin M is a pentamer found in the intravascular
compartment and on the surface of B lymphocytes. It is the
antibody isotype produced initially in the immune response,
and the ﬁrst immunoglobulin class to be synthesized by a
fetus or newborn. IgM antibodies do not cross the placenta,
and for these reasons the demonstration of IgM speciﬁc
antibody is useful in the assessment of neonatal infection.
Dysregulation of IgM leading to elevated or reduced serum
levels has been reported in a number of conditions [8]. In
children, isolated elevated levels of IgM have been associated
with acute or recurrent infections (Hyper-IgM immunode-
ﬁciency, Epstein Barr virus infection) [32, 33]. Fluctuating
levels of serum IgM associated with secondary conditions
in some adult cases may have prognostic signiﬁcance, as in6 Clinical and Developmental Immunology
Table 2: Prevalence of presenting conditions in pediatric and adult patients with SIgMID.
Condition Pediatric frequency percentage (n = 48) Adult frequency [8]p e r c e n t a g e( n = 191)
Pneumonia/lower respiratory tract infection 19.6 5.2
Otitis media 39.2 1.6
Bronchitis 9.8 3.1
Meningitis 7.8 0.5
Nonspeciﬁc bacterial respiratory infection 0 4.7
Upper respiratory infections 9.8 16.2
Failure to thrive 7.8 0
Other infections
∗ 9.8 1.5
Allergic rhinitis 0 11.5
Vasomotor rhinitis 3.9 3.7
Nasal polyps 0 1.5
Asthma 7.8 16.2
Idiopathic angioedema 0 2.6
Idiopathic anaphylaxis 0 2.1
Gastrointestinal disease 13.7 4.2
Asymptomatic 3.9 3.1
Autoimmune disease 3.9 11.5
Skin disease 9.8 4.7
Bronchiectasis 0 2.6
∗Nonrespiratory/nonmeningitis/nonskin.
adult systemic lupus erythematosus (SLE) [34]. Decreased
levels of IgM have been associated with episodes of recurrent
infection, thymic hypoplasia, celiac disease, autoimmune
disease, and certain adult malignancies and several primary
immunodeﬁciencies (Wiskott-Aldrich Syndrome, ataxia-
telangiectasia,CVID,Brutonagammaglobulinemia,SIgMID,
combined IgG and IgM immunodeﬁciency, and transient
hypogammaglobulinemia of infancy) and congenital dis-
orders (Bloom syndrome and Russell-Silver syndrome).
Isolated reduced serum IgM levels secondary to these other
illnesses should be excluded before making a diagnosis of
primary SIgMID. Primary selective IgM immunodeﬁciency
is less common than secondary IgM immunodeﬁciency.
SIgMID has been characterized as a rare primary
immunodeﬁciency diﬀerentiated by a low serum IgM level,
less than 2 SD or <10% of age adjusted normal controls
or absolute levels of 10–20mg/dL in infants and children
[3]. The earliest recognized cases were described in children
in 1966 [9, 19]. More pediatric cases and the ﬁrst adult
cases were described in the late 1960s and were classiﬁed as
dysgammaglobulinemiaV[2,6,12,21].Overthesubsequent
40years,smallseriesandisolatedcasereportshaveappeared.
Recently, a retrospective review with a large cohort of adult
SIgMID was reported further characterizing this illness in
patients ≥18 years of age [8].
H e t e r o g e n e o u sl y m p h o c y t ea b n o r m a l i t i e sh a v eb e e n
reported in patients (mainly adults) with SIgMID. Several in
vitro and in vivo immunologic, phenotypic and functional
proﬁles have been described, some conﬂicting, and are
summarized in Table 3.
Heterogeneous gene impairments regulating terminal
Bc e l ld i ﬀerentiation have been reported in SIgAID [35]
and CVID. Recently, mutations in the inducible T cell
costimulatorgene,thetransmembraneactivatorandcalcium
modulator, and cyclophilin ligand interactor have been
describedinCVIDandSIgAID[36].Similarindepthinvitro
studies of lymphocyte function and molecular genetic stud-
ies have not been applied to pediatric and adult patients with
SIgMID [8]. Functional (except isohemagglutinin titers),
phenotypic or molecular genetic studies were not performed
in our cohort. The latter was not the subject of this analysis.
SIgMID is regarded as an uncommon disorder and often
neglected in the discussion of primary immunodeﬁciencies
[36, 37]. A discussion of SIgMID is notably absent in
recently published practice parameters on primary immun-
odeﬁciencies from expert panels [37]. The prevalence of
S I g M I Dh a sb e e nr e p o r t e dt ob el e s st h a nS I g A I Di na n
unselected group of 3,213 individuals ages 4–87 [1]. In the
atopic population, the prevalence of both SIgAID (4.5%)
and SIgMID (ranging from 1.56–22%) may be higher than
in the general population [38]. The prevalence of SIgMID
in an adult symptomatic population of patients going to
an allergy and immunology practice (1:385) [8]m a yb e
much higher than previously thought (1:15,000) [7]. By
comparison, the prevalence in our pediatric symptomatic
patients going to an allergy and immunology practice was
0.03%—one-tenth of the adult prevalence. Asymptomatic
patientswithSIgMIDhavebeenreported(upto19%insome
series)[14,21,39],butonly2caseswereobservedinchildren
[14, 21]. Asymptomatic pediatric patients with SIgMID wereMarc F. Goldstein et al. 7
Table 3: Immunologic abnormalities in SIgMID.
T cell functions
Increased IgM-speciﬁc T cell suppressor function [35, 40, 41]; normal T cell
suppression function [42–44]
Excessive isotype nonspeciﬁc T cell suppressive activity [40]; increased IgM
speciﬁc suppressive T cell function [35]
Defect in T cell help [10, 26]; normal T cell help [17, 42, 44, 45]
Nonspeciﬁc T cell abnormalities [26]; normal T cell function [42]
B cell function
Defect in B cell diﬀerentiation into IgM-immunoglobulin secreting cells [40, 46,
47]
T and B cell enumeration and phenotype
Normal peripheral T and B cell phenotypes [42, 43, 47, 48]; increased CD8+ cells
a n di n v e r t e dC D 4 / C D 8r a t i o s[ 40]; increased CD4+ cells and decreased CD8+
cells [47]
Reduced number of IgM secreting B cells [45, 46] with a failure of secreted mu
mRNA synthesis [46]; normal surface IgM expression on B cells [10, 17, 35, 43,
47–49]; normal secreted mu mRNA synthesis [49]
Mitogen/antigen stimulation
Mitogen and antigen stimulated B cell proliferation assays with normal IgM
responses [11, 42]; decreased antigen proliferation IgM responses [4, 17, 40, 41,
45–49]
Deﬁcient IgM responses to viral antigens and/or endotoxin containing vaccines
and deﬁcient isohemagglutinin antibodies [24]
Failure to respond to antigen challenge with tetanus toxoid, pneumococcal
vaccine, meningococcus vaccine, Salmonella O and H antigens, and typhus-
paratyphus vaccine [10–12, 19, 42, 50]
Complement No complement deﬁcits [10]
Delayed hypersensitivity
Reduced delayed cutaneous hypersensitivity [10, 17]; normal delayed cutaneous
hypersensitivity [11, 42]
Phagocytosis
Normalphagocytosisandkillingofencapsulatedbacteria[10];nominallyaﬀected
opsoniﬁcation of yeast particles [11]; select opsonic defect against Pseudomonas
[51]
not screened for or identiﬁed in our retrospective practice
database analysis. These cases are typically found during
the investigation of other diseases (autoimmune disease or
cancer) or in family members of patients with immunodeﬁ-
ciencyorbychance.Screeningforasymptomaticcaseswould
be cost prohibitive. In our review, 1 pediatric patient with
a complete deﬁciency of IgM was identiﬁed, reﬂecting the
rarity of such an occurrence [16]. In Cassidy’s population
of 3213 unselected Caucasian individuals, only 1 patient had
undetectable serum IgM levels (0.03% incidence) [1].
Common with other primary immunodeﬁciencies,
recurrent sinopulmonary infections were present in 74.5%
of pediatric SIgMID cases (Table 4). Although meningitis,
sepsis, atypical infections and fatalities secondary to infec-
tions have previously been reported in pediatric SIgMID,
these complications were not seen in our 2 cases. In contrast
to CVID and SIgAID where antibiotics may be used for
extended periods along with prophylactic antibiotics, our
2 pediatric patients with recurrent respiratory infections
responded to conventional courses of antibiotics and were
not treated with prophylactic antibiotics. Also diﬀerent
from CVID and SIgAID, our patients, and the majority of
previously reported pediatric cases, did not receive IVIg.
Two pediatric SIgMID cases with functional IgG antibody
deﬁciency received IVIg [31]. Given these observations,
adult patients with SIgMID and most pediatric cases of
SIgMID experience infections with conventional organisms.
The absence of virulent infections in most cases may be due
to eﬀective antibiotic therapy and/or the response of other
immune systems to microorganisms that may compensate
forthelowlevelofIgM.Inaddition,earlierreportedfatalities
from infections (all prior to 1972) may reﬂect less eﬀective
antibiotic coverage and/or hospital care than that currently
available. Nevertheless, like other primary immunodeﬁcien-
cies. the morbidity of frequent infection in SIgMID is high.
Appropriate immunization (inﬂuenza, H. inﬂuenzae,p n e u -
mococcus, pertussis), attention to concomitant treatment
directed at allergic inﬂammation, and good hygiene are
important preventative measures. Aggressive antimicrobial
therapy is recommended to prevent and manage infectious
complications. IVIg may be instituted in cases of recurrent,
debilitating or life threatening infection, and/or in patients
with concomitant functional IgG deﬁciencies.
Autoimmune phenomena are seen in association with
severalimmunoglobulindeﬁciencysyndromes.Inparticular,
SLE, rheumatoid arthritis, thyroiditis, and autoimmune
h e m o l y t i ca n e m i ah a v eb e e nr e p o r t e di nC V I Da sw e l l
as SIgAID [5, 12]. From our review, in pediatric SIgMID8 Clinical and Developmental Immunology
Table 4: Frequencies of comorbid diseases in patients with SIgMID. (n/a = not applicable).
Disease state
Previously reported
pediatric cases + 2 new
cases percent (n = 51)
Previously reported adults
cases [8] percent (n = 191)
Allergic rhinitis 9.8 12.6
Idiopathic angioedema 0 2.6
Idiopathic anaphylaxis 0 2.1
Asthma 18.7 24
Autoimmune disease∗ 3.9 12
Bronchiectasis 0 2.6
Failure to Thrive 9.8 N/A
Gastrointestinal disease∗∗ 15.7 12
Malignancy 0 2.6
Meningitis 7.8 0.5
Nasal polyps 0 0.5
Other infections∗∗∗ 9.8 1.6
Recurrent respiratory infections 74.5 32.5
Skin disease 11.8 4.7
Thyroid disease 0 0.5
Vasomotor rhinitis 3.9 37
Fatalities 7.8 0
Asymptomatic 3.9 3.1
∗Autoimmune thyroiditis, autoimmune anemia, autoimmune glomerulonephritis, rheumatoid arthritis, SLE.
∗∗Includes celiac disease, inﬂammatory bowel disease, diarrhea syndromes.
∗∗∗Nonrespiratory/nonmeningitis/nonskin.
cases, autoimmune disease is distinctly uncommon (3.9%),
compared to 12% in previously reported adult SIgMID cases
(Table 4)[ 8].
Dysgammaglobulinemia has been reported with several
GI conditions including steatorrhea, nodular lymphoid
hypoplasia, Crohn’s disease, ulcerative colitis, amyloidosis,
disaccharidase deﬁciencies, pernicious anemia, schlerosing
cholangitis, celiac disease and protein losing enteropathies
[4, 20, 50]. In particular, celiac disease has been reported in
associationwithseveralprimaryimmunodeﬁcienciesinclud-
ing isolated severe SIgAID [52, 53] or reduced IgA levels
(20—<60mg/100mL) [20, 54, 55], panhypogammaglobu-
linemia [53] and isolated combined IgA and IgM deﬁciency
[53]. IgM deﬁciency has been more frequently reported—
including 30 of 75 (37%) of adult cases, 5 of 5 childhood
cases [20], 11 of 30 (37%) untreated adult patients [54], 8 of
11 untreated adult patients [55], 6 of 11 untreated, and 2 of 7
treated adult patients [55]. Studies based on catabolism and
distribution of labeled IgM have not shown any diﬀerence in
dietcontrolleduntreatedceliacdisease[55].Wherereported,
SIgMID did not correlate with any speciﬁc biochemical,
hematologic or histologic abnormalities. Jejunal biopsies
of aﬀected patients were no diﬀerent than those of celiac
patients with normal immunoglobulin levels. There was no
unusual risk of infection in these reported patients [55]. Of
note, IgM levels returned to normal levels in most pediatric
and adult patients following a gluten-restricted diet [20, 55].
In one study, mean pretreatment IgM level was 31.4 and
the mean post treatment level 73.6, the diﬀerence being
statistically signiﬁcant (P = .0001) [20]. In those where
the diet restriction was removed, IgM levels fell back to
subnormal levels. It has been suggested that this secondary
form of IgM deﬁciency is related to reduced synthesis from
lymphoreticular dysfunction stimulated by gluten antigen
exposure [54, 55].
The development of lymphoproliferative disorders
and/or other malignancies is a concern with several primary
immunodeﬁciencies, especially CVID [37]. In SIgMID the
risk is relatively low in adults (2.6%) and negligible in
children (0%). Pediatric cases of SIgMID also diﬀer from
adult cases in the absence of reported cases of angioedema,
anaphylaxis,nasalpolyps,bronchiectasis,andthyroiddisease
(Table 4). However, these conditions may become relevant
concerns as children with SIgMID mature into adults.
Vigilant followup and surveillance for these complications
may therefore be warranted.
6. CONCLUSION
Pediatric SIgMID is a rare immunodeﬁciency with a preva-
lence of 0.03% in our symptomatic population. In our
review of 51 pediatric patients with SIgMID, most patients
presented with respiratory infections which, in general, were
not severe or life threatening. The coexistence of autoim-
mune disease was rare, malignancies were not reported,
and 4 fatalities were observed, 3 from fulminant infection,
either meningitis or pneumonia. This report should alert
clinicians to the possibility that SIgMID, although rare,
may be the cause of recurrent respiratory infections in
children. In addition, identiﬁcation of patients with SIgMIDMarc F. Goldstein et al. 9
may prevent some of the complications seen later in life
with adult patients. Larger collaborative studies will better
deﬁne the molecular genetics, pathogenesis, and clinical and
immunologic phenotypes of this disorder in children.
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